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Abstract 
Toll-like receptor 9 (TLR9) is an innate immune sensor for microbial DNA that 
erroneously responds to self DNA in autoimmune disease. To prevent autoimmune 
responses, TLR9 is excluded from the cell surface and silenced until the N-terminal half 
of the ectodomain (TLR9N) is cleaved off in the endolysosome. Truncated TLR9 
(TLR9C) senses ingested microbial DNA, although the precise role of the truncation 
remains controversial. Here we show that TLR9 is expressed on the surface of splenic 
dendritic cells. Following the cleavage of TLR9 in the endolysosome, TLR9N remains 
associated with TLR9C, forming the complex TLR9N+C. The TLR9-dependent 
cytokine production by Tlr9-/- dendritic cells is rescued by a combination of TLR9N and 
TLR9C, but not by TLR9C alone. These results demonstrate that the TLR9N+C 
complex is a bona fide DNA sensor. 
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Introduction 
Toll-like receptors (TLRs) sense a variety of microbial products. Cell surface TLRs, 
including TLR4/MD-2, TLR1/TLR2, and TLR6/TLR2, recognise microbial membrane 
lipids, whereas TLR3, TLR7, TLR8, and TLR9 localise to intracellular organelles and 
recognise microbial nucleic acids 1-3. Self/pathogen discrimination by DNA-sensing 
TLR9 was initially considered to depend on structural differences between self and 
microbial DNA, such as unmethylated CpG motifs 4. However, despite its 
structure-dependent discrimination, TLR9 still has a risk of responding to self DNA 5. 
Self/pathogen discrimination by TLR9 is therefore error-prone and needs to be 
strengthened by endosomal DNA sensing-based mechanisms. 
While self-derived DNA is rapidly degraded by DNase, microbial DNA is resistant to 
degradation because it is encased in bacterial cell walls or viral particles. Microbial 
DNA is therefore able to reach endolysosomes and to stimulate TLR9 6. The aberrant 
transportation of self DNA to endolysosomes has been shown to exacerbate 
autoimmunity 5,7,8. In autoimmune diseases such as systemic lupus erythematosus (SLE) 
or psoriasis, self DNA is complexed with autoantibodies or the cationic antimicrobial 
peptide LL37. These complexes are resistant to DNase and are delivered into endosomal 
compartments via FcR-mediated endocytosis, where they are able to activate TLR9, 
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leading to dendritic cell (DC) activation and the production of type I interferon (IFN-I) 
7,9,10.  
In addition to ligand transportation, sensor transportation is also tightly controlled to 
prevent autoimmunity. TLR9 is reported to be localised mostly to the endoplasmic 
reticulum (ER) and transported to endolysosomes upon activation 11,12. If TLR9 is 
forced to be expressed on the cell surface, TLR9 signals extracellular self DNA, leading 
to systemic lethal inflammation 13. TLR9 sequestration from the cell surface is a second 
mechanism limiting TLR9 activation by self DNA.  
A third mechanism depends on the proteolytic cleavage of TLR9 14,15. After exiting 
the ER, the TLR9 ectodomain is cleaved by asparagine endopeptidase (AEP) and/or 
cathepsins 16,17. Truncated TLR9 (TLR9C), but not full-length (TLR9F), recruits 
MyD88. The precise role of proteolytic cleavage in DNA sensing is, however, still not 
clearly understood. TLR9F is able to sense DNA when its expression on the cell surface 
is forced by a mutation in the transmembrane domain 13.  
Although these mechanisms that restrict TLR9 response to self DNA have been 
characterised, little is known about the expression, distribution, and processing of 
endogenous TLR9. In the present study, we investigate these issues with newly 
established TLR9 monoclonal antibodies (mAbs). TLR9 is unexpectedly detected on the 
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surfaces of splenic DCs but not on bone marrow derived DCs (BM-DCs) or B cells. The 
TLR9 in DCs is mostly cleaved, but the cleaved N-terminal fragment of the 
TLR9-ectodomain (TLR9N) remains associated with truncated TLR9 (TLR9C). TLR9C 
alone fails to sense DNA and requires TLR9N for signalling in response to DNA. These 
results demonstrate that TLR9N+C is a bona fide DNA sensor. 
Results 
Establishment of TLR9N- and TLR9C-specific mAbs 
To study endogenous TLR9, we established three monoclonal antibodies (mAbs) to 
mouse TLR9. The specificities of the mAbs were verified by staining membrane 
permeabilised Ba/F3 cells expressing TLR3, 7, 8, and 9. Anti-mouse TLR9 specifically 
reacted with mouse TLR9 but did not cross-react with human TLR9 (Fig. 1a). Because 
the proteolytic cleavage of the TLR9 ectodomain plays a role in DNA sensing, it was 
important to determine whether the epitopes for these mAbs were in TLR9N or TLR9C. 
We first identified the cleavage sites within TLR9. TLR9-GFP expressed in M12 B cell 
lymphoma was compared to that in PRAT4A-silenced M12 cells. PRAT4A is a 
TLR-specific chaperone18, and TLR9 fails to exit the ER and therefore remains 
unprocessed in the absence of PRAT4A. The fragment missing in PRAT4A-silenced 
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M12 cells is therefore likely to be TLR9C (Fig. 1b). The identified TLR9C fragment 
was purified, and its N-terminal amino acid sequence was determined. TLR9C was 
found to start at 461T or 467F (Fig. 1c). The determined cleavage sites were in the loop 
region between leucine-rich repeat 14 (LRR14) and LRR15 (Fig. 1d), consistent with 
the predictions from previous reports 15,17. The presence of two distinct N-terminal 
fragments of TLR9C might be explained by stepwise processing of TLR9 by asparagine 
endopeptidase and cathepsins 16. According to the N-terminal amino acid sequences, a 
chimeric protein consisting of a signal peptide, N-terminal HA epitope, TLR9 
ectodomain, and transmembrane portion was expressed in Ba/F3 cells. Established cells 
were stained with anti-TLR9 mAb. Two mAbs, J15A7 and B33A4, reacted with TLR9N, 
whereas another mAb, C34A1, bound to TLR9C (Fig. 1e). J15A7 bound to TLR9N 
much less strongly than did B33A4.  
TLR9 is expressed on the surface of splenic DCs 
TLR9 is believed to be sequestered from the cell surface, but endogenous TLR9 
expression on the surface of primary immune cells has never been reported. Using the 
anti-TLR9 mAb, we next addressed the cell surface expression of TLR9. We first 
studied overexpressed TLR9 in Ba/F3 cells. As expected, cell surface TLR9 was not 
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detected on TLR9-expressing Ba/F3 cells, although the TLR9 mAbs did detect 
endosomal TLR9 in membrane permeabilised cells (Fig. 2a). Unc93B1 transports TLR9 
from the ER to endolysosomes 11. Unc93B1 may also play a role in transporting TLR9 
to the cell surface. Unc93B1 was therefore overexpressed in Ba/F3 cells expressing 
TLR9. Both J15A7 and C34A1, but not the other anti-TLR9N, B33A4, detected cell 
surface TLR9 (Fig. 2b). J15A7 also detected cell surface TLR9 on splenic pDCs, 
CD8α+ cDCs, CD4+ cDCs, and double-negative cDCs (Fig. 2c). The specificity of the 
J15A7 staining was verified in Tlr9-/- DCs. Cell surface TLR9 was not detected on 
splenic DCs from Unc93b13d/3d mice harbouring a loss-of-function mutation in the 
Unc93b1 gene19. Taken together with the finding that Unc93B1 overexpression induced 
the cell surface expression of TLR9 on Ba/F3 cells (Fig. 2b), these data suggest that 
Unc93B1 plays an important role in transporting TLR9 to the cell surface.  
In contrast to splenic DCs, BM-pDCs and BM-cDCs did not display easily detectable 
TLR9 on their cell surfaces (Fig. 2d). To gain insight into the mechanism controlling the 
cell surface expression of TLR9 on DCs, BM-cDCs were transduced with retroviral 
vectors encoding TLR9 or Unc93B1. The overexpression of TLR9, but not Unc93B1, 
enabled the detection of cell surface TLR9 on BM-cDCs (Fig. 2e). The co-expression of 
Unc93B1 weakly enhanced the cell surface expression of TLR9. The cell surface 
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expression of TLR9 was positively correlated with the amount of TLR9. B33A4, an 
anti-TLR9N mAb, detected endosomal TLR9 but not cell surface TLR9 on BM-cDCs. 
Splenic B cells, monocytes, and neutrophils were also stained with the anti-TLR9N 
mAb J15A7. Cell surface TLR9 was barely detectable on these cells (Supplementary 
Fig. S1). TLR9 is reported to be expressed on the apical surface of intestinal epithelial 
cells (IEC) and to have a role in regulating colonic inflammation 20. IECs were isolated 
from the mouse gut, and the cell surface expression of TLR9 on IECs was studied. 
TLR9 was undetectable on IECs (Supplementary Fig. S2). In the cells studied, cell 
surface TLR9 was restricted to splenic DCs. 
TLR9N remains associated with TLR9C in endolysosomes 
TLR9N is thought to be cleaved off in endolysosomes 14,16. Little is known about 
whether cleaved TLR9N is secreted, degraded, or remains in endosomes. To address this 
issue, confocal microscopy was used to examine BM-pDCs stained with anti-TLR9N or 
-TLR9C antibodies. Calnexin staining was used to visualise the ER. Anti-TLR9N 
detected TLR9 mostly outside the ER, and its staining pattern showed no apparent 
difference from that of anti-TLR9C (Fig. 3a). Statistical analysis using ZEN confocal 
software (Carl Zeiss Microscopy) showed little significant colocalisation of TLR9 with 
the ER. We next studied Unc93b13d/3d BM-pDCs, in which all the TLR9 remains 
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uncleaved (TLR9F) in ER21. If TLR9 outside the ER is processed, and cleaved TLR9N 
is secreted or degraded, then anti-TLR9N should show much stronger staining in 
Unc93b13d/3d BM-pDCs than in wild-type BM-pDCs. Despite this expectation, two 
anti-TLR9N mAbs were able to detect as much TLR9 in wild type BM-pDCs as in 
Unc93b13d/3d BM-pDCs (Fig. 3b). Moreover, when TLR9N was immunoprecipitated 
from supernatants of Ba/F3 cells expressing TLR9 or TLR9N alone, no secreted TLR9N 
was detectable (Supplementary Fig. S3). These results suggest that TLR9N remained 
intact in endolysosomes after proteolytic cleavage.  
We next asked whether TLR9N is associated with another molecule in endosomes. 
TLR9N is reported to coprecipitate with TLR9F or TLR9C in the RAW264.7 
macrophage cell line 15, suggesting that TLR9N physically associates with TLR9C or 
TLR9F. To confirm this finding with endogenous TLR9 in primary immune cells, 
anti-TLR9C was used to immunoprecipitate TLR9F or TLR9C from BM-cDCs. 
Appreciable amounts of TLR9N coprecipitated with both TLR9C and TLR9F (Fig. 3c, 
lane 2). Similarly, TLR9C was coprecipitated by two anti-TLR9N antibodies (Fig. 3c, 
lane 5 and 8). As a majority of TLR9 is processed in BM-cDCs (Fig. 3c), TLR9C and 
TLR9N are likely to be associated with each other rather than with TLR9F. To 
completely exclude the involvement of TLR9F, TLR9N truncated at 466 and TLR9C 
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beginning at 467 were expressed in Ba/F3 cells, which do not express detectable levels 
of endogenous TLR9 22. TLR9N and TLR9C both migrated much more rapidly in 
SDS-PAGE than TLR9N or TLR9C processed from TLR9F (Fig. 3d, compare lane 2 to 
lane 3 for TLR9N or to lane 4 for TLR9C), most likely due to defects in glycosylation. 
The faster migration in SDS-PAGE was not altered by the coexpression of the other 
fragment, TLR9N or TLR9C (Fig. 3d, compare lane 3 to lane 5 for TLR9N or lane 4 to 
lane 5 for TLR9C). When TLR9C and TLR9N were immunoprecipitated, the other 
fragments were weakly but appreciably coprecipitated (Fig. 3d, lane 5). These results 
demonstrate a direct association between TLR9N and TLR9C.  
The C-terminal LRR of TLR9N mediates its binding to TLR9C  
Extra amino acid residues between LRR14 and LRR15 (441-470) are predicted to form 
a loop protruding from the LRRs that contains the cleavage site 23. Consistent with this 
model, TLR9C began at 461T or 467F, both of which are close to the end of the loop 
and the beginning of LRR15. To investigate the role of these extra amino acids in 
TLR9N in its interaction with TLR9C, TLR9Ns truncated at 440 or 454 were expressed 
in Ba/F3 cells, and the cells were then stained with TLR9 mAbs. B33A4 bound to 
TLR9N (N466), either alone or with TLR9C (Fig. 3e). The staining pattern of J15A7 
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was distinct from that of B33A4. Whereas J15A7 and B33A4 exhibit comparable levels 
of binding to full-length TLR9-expressing cells, J15A7 binds to TLR9N-expressing 
cells much less strongly than does B33A4. When TLR9C was co-expressed with 
TLR9N, however, J15A7 binding was comparable to that of B33A4 (Fig. 3e). This 
suggests that J15A7 is likely to react preferentially with the TLR9N+C complex over 
TLR9N alone, most likely due to a conformational change induced in TLR9N in the 
absence of TLR9C. The truncation of TLR9N at 454 or 440 did not alter B33A4 
staining or the TLR9C-dependent augmentation of J15A7 binding to TLR9N (Fig. 3e), 
suggesting that the extra amino acids in TLR9N are not directly involved in assembling 
TLR9N+C. The tandem repeats of the leucine-rich motif (LRM) are stabilised by 
hydrogen bonds between adjacent LRMs 23. The interaction between TLR9N and 
TLR9C may depend on hydrogen bonds between LRR14 and LRR15. To address this 
possibility, TLR9N lacking LRR14, i.e., TLR9N truncated at 414 (N414), was studied. 
N414 was detected by B33A4, demonstrating that the global structure of TLR9N is not 
altered by the truncation. J15A7 only weakly detected N414 alone, and the 
co-expression of TLR9C failed to augment J15A7 staining (Fig. 3e). To exclude the 
possibility that J15A7 does not interact with N414 alone, N414 was expressed as a 
fusion protein, as shown in Fig. 1e, and stained by J15A7. In the context of the fusion, 
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J15A7 interacted with N414 as strongly as it did with N454 (Supplementary Fig. S4). 
Further, N414 was expressed in BM-cDCs with or without TLR9C. J15A7 bound to 
N414 weakly but appreciably, similar to its binding to TLR9N (N466), but the binding 
was not augmented by TLR9C coexpression (Fig. 3f). These results strongly suggest 
that LRR14 is required for the interaction of TLR9N with TLR9C.  
TLR9N is required for DNA sensing 
The role of TLR9N in TLR9 signalling was then studied. Previous studies have 
demonstrated that TLR9C alone is able to bind to its ligand and recruit the signalling 
adaptor MyD88 14,15. TLR9F, in contrast, is able to bind to DNA but unable to recruit 
MyD88 14. The association of TLR9N with TLR9C led us to examine the role of 
TLR9N in TLR9C signalling. TLR9 and MyD88 were overexpressed in M12 B cells. 
Anti-TLR9N or -TLR9C antibodies were used for immunoprecipitation, and the 
coprecipitation of MyD88 was examined. Anti-TLR9N and anti-TLR9C both 
coprecipitated MyD88, and the degree of coprecipitation increased with CpG-B 
stimulation (Fig. 4a). MyD88 coprecipitation with anti-TLR9N demonstrated that 
MyD88 was recruited to either TLR9F or TLR9N+C. If TLR9F is unable to recruit 
MyD8814, then TLR9N+C is likely to induce signalling in response to DNA. To exclude 
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the involvement of TLR9F, we studied Ba/F3 cells expressing TLR9N, TLR9C, or both. 
These cells also expressed a reporter construct that drives the expression of green 
fluorescent protein (GFP) in response to NF-κB activation. The cells were stimulated 
with CpG-B, and GFP induction was measured. Ba/F3 cells expressing TLR9C alone 
failed to reproduce DNA sensing by TLR9C 15. GFP was induced only when TLR9N 
was co-expressed with TLR9C (Fig. 4b). The requirement for the loop between LRR14 
and LRR15 was next investigated using TLR9N truncated at 440 or 454. TLR9 
responses were not impaired by TLR9N truncation to 440 (Fig. 4b). Thus, the loop 
between LRR14 and LRR15 is not required for TLR9-dependent NF-κB activation. In 
contrast, TLR9N lacking LRR14 (N414) failed to confer DNA-dependent NF-κB 
activation in the presence of TLR9C, demonstrating a correlation between TLR9N+C 
complex formation (Fig. 3e and 3f) and TLR9 response. 
To further study the responses of TLR9N+C, Tlr9-/- BM-cDCs were transduced with 
retroviral vectors encoding TLR9, TLR9N, TLR9C, or TLR9N + TLR9C. TLR9 
expression was confirmed by staining membrane-permeabilised cells with the 
anti-TLR9 mAb (Fig. 5a). TLR9F and TLR9C were expressed in over 80% of Tlr9-/- 
BM-cDCs. The expression of TLR9N+C was estimated based on the TLR9C-dependent 
augmentation of J15A7 binding to TLR9N. More than 50% of cells were considered 
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J15A7high. These BM-cDCs were stimulated with lipid A, CpG-A, or CpG-B, and the 
resulting levels of IL-12p40, TNFα, and IFNβ were determined by ELISA. 
Complementation with TLR9N+C was able to induce all the cytokines studied to the 
same degree observed for TLR9 (Fig. 5b), demonstrating that TLR9N+C is a 
DNA-sensing complex.  
Discussion 
The newly established mAbs to TLR9N or TLR9C have been used to identify 
TLR9N+C as bona fide DNA-sensing form of TLR9. TLR9 that is overexpressed is 
reported to be completely cleaved in the phagosome14. Here, the majority of endogenous 
TLR9 in the steady state DCs is shown to be processed and to reside outside the ER. A 
previous report showed that TLR9N is associated with TLR9C or TLR9F in a 
macrophage cell line15. Consistent with this observation, endogenous TLR9N in 
BM-cDCs remains associated with TLR9C. Although TLR9C alone is reported to 
respond to DNA, TLR9C requires TLR9N for DNA sensing. TLR9N+C is primarily 
responsible for the DNA-dependent TLR9 responses observed in DCs. A previous study 
using deletion mutations at TLR9N suggested that TLR9N is required for interaction 
with DNA and subsequent TLR9 activation24. In the present study, we employs another 
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approach, a complementation strategy, and similarly concludes that TLR9N is required 
for TLR9 responses. Even when TLR9N and TLR9C are independently produced in the 
ER, they are able to self-assemble. TLR9N+C is able to activate an NF-κB reporter in 
the Ba/F3 cell line and to induce the expression of a variety of cytokines, including 
TNFα, IL-12p40, and IFNβ, in Tlr9-/- BM-cDCs. Considering that IRF7 activation is 
required for IFNβ production 25, these findings show that TLR9N+C is able to activate 
IRF7-dependent signalling pathways as well as NF-κB-dependent pathways. Although 
TLR9C alone is reported to interact with DNA14,15, this interaction, if it occurs, does not 
activate downstream signalling pathways in our experimental systems. The DNA ligand 
induces an allosteric change in the cytoplasmic signalling domain of the preformed 
TLR9 dimer26. The interaction of DNA with TLR9C alone may not be sufficient to 
induce this allosteric change.  
TLR ectodomains consist of the tandem repeats of LRM, which is typically 24 amino 
acids in length 23. The LRM adopts a loop structure, beginning with a short β-strand 
followed by a β-turn. Tandem repeats of LRM form a solenoid structure with parallel 
β-sheets. Consecutive β-sheets and β-turns form a continuous hydrogen-bonded, packed 
structure, generating a curved solenoid with the β-sheets on the concave side. TLR 
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ectodomains are stabilised by their interior hydrophobic cores and hydrogen bonds 
between adjacent β-sheets 23. The LRRs of the TLR ectodomains, especially those of 
TLR7, 8, and 9, are longer than 24 amino acids. The extra residues form a loop that 
protrudes from the convex or planar side of the LRR solenoid. A tentative loop is 
thought to be located between LRR14 and LRR15 in the TLR9 ectodomain and is 
predicted to be cleaved15. Consistent with this prediction, the present study shows that 
TLR9C begins at the C-terminal end of the loop. Considering that the protruding loop 
does not contribute to either the inner hydrophobic bonds or the hydrogen bonds 
between β-sheets, the proteolysis of the loop is not likely to influence the basic solenoid 
structure. The association between TLR9N and TLR9C is likely to be mediated by the 
hydrogen bonds between the β-sheets of LRR14 and LRR15, not by the loop between 
LRR14 and LRR15. This hypothesis is supported by the behaviours of the TLR9N 
mutants. A TLR9N construct lacking the loop (N440) is able to confer 
DNA-responsiveness to TLR9C, but TLR9N lacking LRR14 (N414) is not. J15A7 
staining of TLR9N is amplified by TLR9C coexpression, suggesting that J15A7 
preferentially binds to TLR9N+C over TLR9N alone. Amplification induced by TLR9C 
coexpression is observed for N440 but not N414, indicating that N414 fails to associate 
with TLR9C. Therefore, LRR14 is required for the interaction of TLR9N with TLR9C. 
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Although TLR9N has been reported to be dispensable for the TLR9 response14,15, the 
present study shows that TLR9N is required for TLR9 responses. It is possible that 
uncleaved TLR9F is not competent for DNA sensing and that TLR9 proteolytic 
cleavage activates this activity. Uncleaved TLR9F is, however, reported to be activated 
in vivo when its expression on the cell surface is forced 13. These results suggest that 
TLR9F is able to respond to DNA. The role of proteolytic cleavage in the TLR9 
response remains unresolved but can be addressed by comparing TLR9 and TLR9N+C. 
Complementation with TLR9 generates both TLR9F and TLR9N+C, whereas 
complementation with TLR9N + TLR9C generates TLR9N+C only. A comparison of 
the cytokine production by BM-cDCs complemented with TLR9 and TLR9N + TLR9C 
reveals no significant differences. Future studies should focus on other cell types, such 
as B cells and pDCs.  
Another mechanism of TLR9 silencing, exclusion from cell surface, is found to be 
leaky in splenic DCs. Cell surface TLR9 is detected on splenic DCs but not BM-cDCs. 
Cell surface TLR9 is detectable on TLR9-overexpressing BM-cDCs but not 
Unc93B1-overexpressing cells. In BM-cDCs, TLR9 expression may not be sufficient 
for its cell surface expression. Considering that the forced expression of TLR9 on the 
cell surface causes lethal systemic inflammation 13, cell surface TLR9 expression is 
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likely to be silenced in splenic DCs. The TLR9N mAb J15A7 is able to detect cell 
surface TLR9 on splenic DCs in normal mice, whereas the other TLR9N mAb, B33A4, 
is not. Given that B33A4 mAb detects both TLR9F and TLR9N+C in endosomes, the 
failure of B33A4 mAb to detect cell surface TLR9 is unlikely to be due to the cleavage 
of the TLR9 ectodomain. Rather, cell surface TLR9 is likely to adopt a conformational 
state distinct from that of endosomal TLR9. This distinct conformation may be linked to 
TLR9 silencing on the cell surface. Further studies are needed to characterise the 
functional difference between cell surface and endosomal TLR9.  
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Methods 
Reagents and Antibodies 
Pam3CSK4 was purchased from EMC microcollections. Lipid A Re:595 was purchased 
from Sigma-Aldrich. CpG-A 1585 (G∗G∗GGTCAACGTTGAG∗G∗G∗G∗G∗G; asterisks 
represent phosphorothioated bases) was synthesised by Hokkaido System Science. 
CpG-B 1688 (5′-TCCATGACGTTCCTGATGCT-3′, all phosphorothioated) was 
synthesised by FASMAC. Recombinant mouse GM-CSF was purchased from R&D 
Systems. Recombinant murine Flt-3 ligand was purchased from PeproTech. Digitonin 
was purchased from WAKO and Nacalai. The anti-FLAG antibody and puromycin were 
purchased from Sigma-Aldrich. G418 was purchased from Nacalai. Anti-HA 
antibody–conjugated beads and the anti-HA antibody (clone 3F10) were purchased 
from Roche. The rabbit anti-GFP polyclonal antibody (pAb) used for western blotting 
was purchased from Invitrogen, and the anti-GFP (FM264) mAb used for 
immunoprecipitation was previously generated in our laboratory 27. For immunoprobing 
TLR9C, a rabbit pAb against the TIR domain was developed in our laboratory. For 
immunoprobing TLR9N, a rabbit pAb against amino acids 200-300 of mouse TLR9 (# 
ab13928) was purchased from Abcam. 
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Plasmid constructs 
The C termini of mouse TLR3, 7, 8 and 9, human TLR9, Unc93B1, and Myd88 were 
tagged with FLAG-6xHis, HA, or GFP epitopes as indicated in the figures. They were 
generated by PCR and cloned into retroviral pMX, pMXpuro, or pMXneo vectors 
(kindly provided by Dr Kitamura, Tokyo, Japan). To suppress mouse PRAT4A 
expression in M12 cells, we also constructed the shRNA-expressing retroviral vector 
pSSCH, as described previously 27. For the constructs encoding TLR9N fragments (Fig. 
3 and 4), TLR9 fragments corresponding to amino acids 1-414 (TLR9N414), 1-440 
(TLR9N440), 1-454 (TLR9N454), or 1-466 (TLR9N466) were cloned into the pMX 
vector. For the TLR9C constructs, TLR9 fragments corresponding to amino acids 1-35 
(the signal peptide and following 10 amino acids) fused to amino acids 441-1032 
(441TLR9C), 455-1032 (455TLR9C), or 467-1032 (467TLR9C) were cloned into the 
pMX vector using the In-Fusion HD cloning kit (Clontech Laboratories, Inc.).  
Mice and cell lines 
C57BL/6 mice were purchased from Japan SLC, Inc. (Shizuoka, Japan). The Tlr9-/- 
mice were kind gifts from Prof Shizuo Akira (Osaka Univ., Japan). The Unc93B13d/3d 
mice were kindly provided by Prof Bruce Beutler and the Scripps Research Institute. 
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Mice were maintained in the animal facility of the Institute of Medical Science at the 
University of Tokyo and all studies using mice were approved by the Institutional 
Animal Care and Use Committee. Ba/F3 cells and M12 cells were cultured in Roswell 
Park Memorial Institute (RPMI) 1640 medium supplemented with 10% FBS, 100 
units/ml penicillin, 100 μg/ml streptomycin, 300 μg/ml glutamine, and 50 μM 2-ME. 
IL-3 was added to the culture medium for the Ba/F3 cells. The construction of a Ba/F3 
line with NF-κB-GFP (BaκB) was described previously 22. 
Retroviral transduction 
The pMX, pMXpuro, and pMXneo vectors were transfected into Plat-E packaging cells 
with FuGene6 (Roche). After 2 days of incubation, supernatants were obtained as virus 
suspensions. Cells were infected using a mixture of virus suspension and DOTAP 
(Roche).  
Induction of DCs and macrophages from BM cells 
BM-cDCs and BM-pDCs were prepared as described previously22. Briefly, bone 
marrow cells were flushed from mouse tibiae and femurs. The RBCs were lysed, and 
the remaining cells were cultured at 37°C for 1 week in RPMI 1640 medium 
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supplemented with 10% FCS, penicillin-streptomycin-glutamine, and 50 mM 2-ME. 
Macrophage, cDC, and pDC differentiation was induced by 100 ng/ml M-CSF, 10 
ng/ml GM-CSF, and 50 ng/ml Flt3 ligand, respectively. 
Retroviral transduction of BMDCs 
Bone marrow (BM) cells from TLR9-deficient mice were cultured with 10 ng/ml of 
recombinant murine GM-CSF. After 3 days of culture, cells were seeded on 24-well 
tissue culture dishes at 5×105 cells per well in 150 µl of RPMI 1640 medium 
supplemented with 10% FCS. A 250 µl aliquot of retroviral suspension and 250 µl of 
medium were added to the BM cells with 15 ng/ml of recombinant murine GM-CSF 
and 6 µg/ml of DOTAP. For co-transduction with multiple vectors, 250 µl of each 
retrovirus suspension encoding two different truncated TLR9 were added to the BM 
cells as described above. Cells were centrifuged at 840 x g for 60minutes at room 
temperature. On the next day, 1 ml of medium supplemented with GM-CSF was added. 
The retrovirus transduction procedure was repeated on days 5 and 7, and fresh medium 
was added on the days following each transduction. On day 9, all media, including the 
retroviruses, were removed; the cells were washed three times; and fresh medium 
supplemented with GM-CSF was added. On day 10, the BMDCs were harvested and 
stimulated with TLR ligands. 
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ELISA 
The cytokine and interferon levels in the culture supernatants were measured with 
ELISA kits (R&D Systems). 
TLR9 cleavage site analysis 
GFP-tagged mouse TLR9 was stably expressed in M12 cell line. Aliquots of 1×1010 
cells were collected and prepared for immunoprecipitation in lysis buffer (150 mM 
NaCl, 50 mM Tris·HCl (pH 7.4), 0.5% Triton X-100, 10 µg/ml aprotinin, 10 µg/ml 
leupeptin, 1 mM PMSF). Anti-GFP agarose beads (MBL, Japan) were added to the 
lysate and incubated overnight at 4°C. The beads were collected and washed four times 
in washing buffer (150 mM NaCl, 30 mM Tris·HCl (pH 7.4), 0.1% Triton X-100), and 
the precipitated protein was eluted in buffer (150 mM NaCl, 30 mM glycine·HCl (pH 
2.5), 0.1% Triton X-100). The eluted sample was dialysed against a new buffer (10 mM 
NaCl, 0.1% Triton X-100) and concentrated by freeze drying. The concentrated sample 
was reconstructed in sample buffer (2% SDS, 10% glycerol, 62.5 mM Tris·HCl (pH 
6.8), 0.025% bromophenol blue, 5% 2-ME) and subjected to SDS-PAGE. The separated 
protein was transferred to a PVDF membrane in CAPS transfer buffer. Transferred 
protein was visualised by Coomassie Blue, and the band corresponding to the 
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C-terminal fragment of TLR9C was cut out. The TLR9C gel band was subjected to 
N-terminal amino acid analysis, and the amino acid sequence was detected by APRO 
Science Co., Ltd. (Japan). 
Confocal imaging 
BM-pDCs were stained with anti-CD11c-Pacific Blue and anti-B220-APC to enable the 
sorting of CD11c+B220+DC cells with a FACSAria instrument. The sorted pDCs were 
allowed to adhere to coverslips overnight and were then fixed in 4% paraformaldehyde 
for 10 min and permeabilised with 0.1% Triton X-100 in 2.5% BSA Blocking One for 
30 min. pDCs were incubated with anti-TLR9 and anti-Calnexin primary antibodies 
(Abcam) for 90 min at 37°C, washed, and then incubated with Alexa Fluor 488- or 
568-conjugated secondary antibodies (Invitrogen) for 90 min at 37°C. The 
immunostained pDCs were examined under an LSM710 confocal microscope with a 
63× NA1.4 Plan-Apochromat oil immersion lens (Carl Zeiss Microscopy). Fluorescent 
images were acquired and analysed using the LSM710 ZEN software. The 
colocalisation of TLR9 with Calnexin was analysed using LSM710 ZEN according to 
the manual provided with the software. At least two independent measurements were 
conducted for each image. Pearson’s correlation coefficients were used for the statistical 
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analysis of colocalisation. The Pearson’s coefficients are shown as absolute values. A 
Pearson’s coefficient <0.2 represents poor colocalisation.  
Anti-mouse TLR9 monoclonal antibodies 
To establish a monoclonal antibody (mAb) against mouse TLR9, BALB/c Tlr9-/- mice 
were immunised with Ba/F3 cells expressing mouse TLR9 (Ba/F3_mTLR9). Four days 
after the final immunisation, splenic cells were fused with SP2/O myeloma cells. 
Hybridomas that produced anti-mouse TLR9 mAbs were selected by flow cytometry 
staining of the Ba/F3 cells used for immunisation. Three mAbs, J15A7 (IgG1/κ), 
C34A1 (IgG2a/κ), and B33A4 (IgG2a/κ), were isolated and used in the present study. 
We used these antibodies at the following concentrations: for cell surface staining: all 
antibodies, 0.2 µg/ml; for internal staining, J15A7, 0.2 µg/ml, C34A1, 0.075 µg/ml, 
B33A4, 0.075 µg/ml; for confocal microscopy: all antibodies, 1 µg/ml. 
Cell staining 
For the staining of BM cells and splenocytes, cells were preincubated with 
anti-CD16/CD32 (clone: 93) and stained with fluorescein-conjugated antibodies 
specific to the following markers for flow cytometry analysis: CD4 (GK1.5), CD8α 
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(53-6.7), CD11c (HL3), B220 (RA3-6B2), and PDCA-1 (927, 129c1). Single cell 
splenocyte suspensions were prepared as described previously 28. Cells were incubated 
at 4°C with biotinylated mAbs diluted in staining buffer (1 × PBS with 2.5% FBS and 
0.1% NaN3), followed by incubation with a streptavidin-conjugated antibody. For the 
internal staining, cells were permeabilised with 0.05% or 0.1% saponin (Sigma-Aldrich 
S5421 or WAKO 193-00162) in staining buffer; subsequent steps were performed in 
saponin buffer. Stained cells were analysed with FACSCalibur or FACSAria flow 
cytometers (BD Biosciences). 
Immunoprecipitation and western blotting 
Cells were washed and lysed in lysis buffer consisting of 1% digitonin, 20 mM Tris·HCl 
(pH 7.4), 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 10% glycerol, 1 mM DTT and 
Complete Protease Inhibitor Cocktail (Roche). After incubation on ice, the lysates were 
centrifuged, and the debris was removed. For immunoprecipitation, anti-HA matrix 
(Roche, clone 3F10) or N-hydroxysuccinimide-activated Sepharose 4FF beads coupled 
to the anti-mouse TLR9 mAb were added to the cell lysates and incubated at 4°C. Then, 
the beads were washed three times with 0.1% digitonin, and the bound proteins were 
eluted by boiling in SDS sample buffer (125 mM Tris·HCl (pH 6.8), 20% glycerol, 4% 
27 
 
SDS, 10% 2-ME, 0.005% bromophenol blue). After electrophoresis, samples were 
transferred to PVDF membranes and subjected to immunoblotting. 
Intestinal epithelial cells 
The intestines were opened longitudinally and washed extensively several times with 
ice-cold PBS. The intestinal tissue was then cut into 0.5-cm pieces and incubated in 1 mM 
EDTA/PBS at 37°C for 20 min with gentle shaking. After passage through a 70-μm cell 
strainer, the cells were washed twice with DMEM containing 20% foetal calf serum 
(FCS). The isolated cells were stained with anti-EpCAM (eBioscience, clone G8.8), 
anti-CD45 (Biolegend, clone 30-F11) Abs and 7-aminoactinomycin D (7-AAD, BD). 
The 7-AAD-/CD45-/EpCAM+ cells were considered intestinal epithelial cells (IECs) and 
used for the further analysis of TLR9 expression. 
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Figure legends 
Figure 1 | Establishment of anti-mouse TLR9 mAbs. (a) 
Membrane-permeabilised Ba/F3 cells expressing mouse TLR3, 7, 8, 9, or human TLR9 
were stained with anti-TLR9 or anti-FLAG antibodies as indicated. TLRs were tagged 
with the FLAG epitope at the C-terminus. (b) TLR9-GFP was expressed in a B cell 
lymphoma line M12 (lane 1) or PRAT4A-silenced M12 (lane 2), immunoprecipitated, 
and immunoprobed with anti-GFP. Full-length (TLR9F) and truncated TLR9 (TLR9C) 
are indicated. Nonspecific bands are indicated by asterisks. (c) The first amino acids of 
the TLR9C isoforms, as determined by N-terminal amino acid sequencing, are indicated 
by arrowheads. The human TLR9 amino acid sequence is also shown. (d) Schematic 
representation of the cleavage sites in the TLR9 ectodomain. LRR: leucine-rich repeats. 
(e) Ba/F3 cells expressing the HA epitope, TLR9 ectodomain (TLR9 (26-818), TLR9N 
(26-454), or TLR9C (468-818)), and transmembrane region were established. These 
cells were membrane permeabilised and stained with anti-TLR9 or -HA antibodies. The 
grey histograms represent cells that stained with the second reagent alone. These 
experiments were repeated three times, and representative data are shown. 
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Figure 2 | TLR9 is expressed on the surface of splenic DCs. Ba/F3 cells 
expressing TLR9 alone (a) or TLR9 and Unc93B1 (b) were stained with the three 
anti-TLR9 antibodies. The upper panels show cell surface staining, whereas the lower 
panels show staining after membrane permeabilisation. (c) Splenic cells from wild-type, 
Unc93b13d/3d, or Tlr9-/- mice were stained with anti-TLR9 J15A7 together with mAbs 
against the indicated DC markers. The grey histograms represent cells that were not 
stained with the anti-TLR9 mAb. (d) BM-pDCs and BM-cDCs were stained with 
CD11c and B220 (BM-pDC) or CD11c (BM-cDCs) and anti-TLR9 J15A7. Open 
histograms show the proportion of CD11c and B220 (BM-pDCs) or CD11c 
(BM-cDCs)-gated cells that expressed TLR9. The upper panels show cell surface 
staining, whereas the lower panels show staining after membrane permeabilisation. 
Grey histograms represent cells that did not exhibit anti-TLR9 staining. These 
experiments were repeated twice, and representative data are shown. (e) BM-cDCs were 
transduced with retroviral vectors encoding GFP, Unc93B1-mCherry, or TLR9-GFP. 
BM-cDCs were subjected to cell surface staining or membrane permeabilisation and 
staining with anti-TLR9 mAbs. Grey histograms represent cells that were not stained 
with anti-TLR9.  
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Figure 3 | TLR9N remains associated with TLR9C in endolysosomes. (a) 
BM-pDCs were stained with anti-TLR9N J15A7 or -TLR9C C34A1. Cells were 
counterstained with anti-Calnexin to locate the ER. Merged images are also shown. 
Scale, 5 μm. (b) BM-pDCs from wild-type and Unc93b13d/3d mice were subjected to 
membrane permeabilisation and staining with anti-TLR9 as indicated. Grey histograms 
represent cells that stained with the second reagent alone. (c) BM-cDCs from wild-type , 
Unc93b13d/3d and Tlr9-/- mice were subjected to immunoprecipitation with the indicated 
mAbs and immunoprobing with anti-TLR9N or anti-TLR9C antibodies. (d) TLR9, 
TLR9N truncated at 466 (TLR9N) or TLR9 lacking the TLR9N region from 36 to 466 
(TLR9C) were expressed in Ba/F3 cells expressing Cathepsin L, Unc93B1, and the 
NF-κB–GFP reporter construct as indicated. These cells were subjected to 
immunoprecipitation with anti-TLR9N or anti-TLR9C and immunoprobing. (e) TLR9, 
TLR9 lacking 36-466 (TLR9C), and TLR9 truncated at 466, 454, 440, or 414 (N466, 
N454, N440, or N414) were expressed in Ba/F3 cells expressing cathepsin L, Unc93B1, 
and NF-κB–GFP, as indicated. These Ba/F3 cells were subjected to membrane 
permeabilisation and staining with the indicated anti-TLR9 mAbs. These experiments 
were repeated at least twice. (f) BM-cDCs were transduced with TLR9N (N466) or 
N414 with or without TLR9C. These cells were then stained with anti-TLR9N mAbs. 
37 
 
The grey histograms represent cells that were not stained with anti-TLR9. These 
experiments were repeated twice, and representative data are shown.  
 
Figure 4 | TLR9N is required for signalling in response to DNA. (a) M12 B 
cells expressing TLR9 and MyD88-HA were stimulated with CpG-B (0.9 μM) and 
subjected to immunoprecipitation with anti-TLR9N B33A4, -TLR9C C34A1, or -HA 
and immunoprobing with anti-TLR9C or anti-TLR9N, as indicated. An unrelated cell 
line (Ba/F3) and plain M12 were used as negative controls. (b) The Ba/F3 cells shown 
in Fig. 3E were left unstimulated or stimulated for 24 h with 100 nM, 500 nM CpG-B or 
1 µg/ml Pam3CSK4 as indicated. The level of GFP induction was determined by flow 
cytometry. These experiments were repeated twice, and representative data are shown. 
 
Figure 5 | TLR9N+C is able to complement TLR9-dependent cytokine 
production in Tlr9-/- BM-cDCs. (a) Tlr9-/- BM-cDCs were transduced with a 
retroviral vector encoding GFP as a negative control, TLR9, TLR9N (N466), TLR9C, or 
TLR9N+TLR9C. BM-cDCs were subjected to membrane permeabilisation and staining 
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with anti-TLR9 mAbs. Grey histograms indicate the cells that were stained by the 
second reagent alone. The gates for positivity and the positive percentages are also 
shown. The gate for J15A7 was considered to represent TLR9N+C cells. (b) BM-cDCs 
were stimulated with lipid A or TLR9 ligands, and the production of the indicated 
cytokines was determined by ELISA. The values show the averages and S.D. from 
triplicate experiments (wells). The experiments were repeated twice, with the same 
results.  
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Supplementary Figure S1. Cell surface expression of TLR9 on splenic B cells and 
monocytes. (a) Splenic cells were stained with mAbs to CD19, B220, CD21, CD23, and 
TLR9 (J15A7 mAb). Open histograms represent CD19+ B220+ CD23+ CD21- follicular 
(FC) or CD19+ B220+ CD23- CD21+ marginal zone (MZ) B cells with TLR9 staining. (b) 
Splenic cells were stained with mAbs to CD11b, CD11c, Ly6C, Ly6G, and TLR9. Open 
histograms represent CD11b+ CD11c- Ly6G- Ly6Clow monocytes, CD11b+ CD11c- Ly6G- 
Ly6Chigh monocytes, and CD11b+ CD11c- Ly6G+ Ly6C+ granulocytes with cell surface 
TLR9 expression. Grey histograms indicate cells without J15A7 mAb staining. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S2. Cell surface TLR9 is not detected on intestinal epithelial 
cells. Intestinal epithelial cells (IECs) were isolated, and their identity was confirmed 
by staining with CD45 and EpCAM. CD45- EpCAM+ IECs were stained with anti-TLR9 
mAb J15A7. Grey histograms represent IECs from Tlr9-/- IECs, whereas open 
histograms represent IECs from wild-type mice.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S3. TLR9N is not secreted into the culture supernatant. 
Culture supernatants (50 ml) from untransduced Ba/F3 cells or Ba/F3 cells expressing 
TLR9, TLR9N, or TLR9N+TLR9C were collected and immunoprecipitated with the 
mAb against TLR9N (B33A4). The precipitated TLR9N was subjected to SDS-PAGE 
and immunoblotting (lane 4-7). To identify TLR9N, cell lysates from Ba/F3 cells 
expressing TLR9 or TLR9N were also subjected to immunoprecipitation and 
immunoblotting (lane 1-3).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S4. J15A7 reacts with TLR9N lacking LRR 14 (N414). Ba/F3 
cells expressing a fusion protein consisting of the HA epitope, TLR9 ectodomain (TLR9F 
(26-818), TLR9C (468-818), TLR9N (26-454 or 26-414)), and a transmembrane portion 
were established. These cells were subjected to membrane permeabilisation and 
staining with anti-TLR9 mAbs. Grey histograms indicate cells that stained with the 
second reagent alone. These experiments were repeated three times, and representative 
data are shown. 
